Enveda
What They Do & Why Kinnevik is Invested
Enveda is revolutionizing drug discovery by tapping into the vast potential of life’s chemical diversity. Using its AI-driven search engine, the company decodes and maps the complex chemistry found in living systems, unlocking an untapped dark chemical space and discovering novel drug candidates.
Founded by molecular biologist Viswa Colluru – formerly of Recursion, another Kinnevik company (glance to your right) – Enveda was built on the belief that nature holds answers to many diseases. Though some of the most successful drugs in human history came from plants, nature-inspired drug discovery declined because of the slow, inefficient and difficult process of interpreting plant chemistry. Enveda overcomes this through its proprietary platform built around mass spectrometry, machine learning and advanced robotics.
In the four years since its seed round, Enveda’s platform has generated 16 preclinical programs, over 10 development candidates, five assets in IND-enabling studies, and one candidate that entered the clinic in Q4 2024. Over the next 1-2 years, Enveda is dedicated to advancing key programs to critical value-inflection milestones, partnering select programs to unlock near-term value through strategic business development.
Kinnevik is attracted by Enveda’s innovative, nature-based approach to drug discovery and its potential to redefine how we discover treatments. By combining novel AI with deep scientific expertise, Enveda addresses longstanding challenges in uncovering effective treatments, positioning itself as a highly promising player in the sector.
Key Information
- Clinical-stage biotech pioneering small molecule drug discovery inspired from life’s chemistry
- Leverages mass spectrometry, robotics and advanced machine-learning techniques to map life’s chemistry and uncover novel therapeutics
- Focused on advancing novel drugs to critical value-inflection milestones through internal development, retaining optionality of partnering out selective programs
News in the Quarter
- Announced that global pharmaceutical company Sanofi has joined the company’s recent funding round
- Expanded the clinical application of its lead asset, ENV-294, to include asthma. To support this advancement, the company assembled an advisory board of renowned researchers and scientists
